WXIBF News and Press, Wuxi Biologics Cayman Inc From 07/19/23

2023-07-19 05:32:00 ET Summary The drug outsourcing services company is spinning off its WuXi XDC unit, seizing on investor enthusiasm for a new generation of highly targeted ADC drugs. WuXi XDC has filed for a Hong Kong IPO, calling itself the world’s second largest provid...

2023-06-14 06:28:00 ET Summary We’ve seen signs of improvement that are positive for the Chinese internet services sector, but that space also continues to be a place of extreme competitive aggression. As a result of the creation of economic zones, increased availability of...

2023-05-08 14:56:19 ET Summary WuXi Biologics (Cayman) Inc.'s short-term and mid-term financial guidance suggests that the company's revenue and earnings growth rates will be slower than what they were in recent years. Potential financing difficulties for the company's customers a...

2023-05-04 05:21:00 ET Summary Baron Emerging Markets Fund gained 2.68% (Institutional Shares) during the first quarter of 2023, while its principal benchmark Index, the MSCI EM Index, returned 3.96%. The Fund may invest in companies of any market capitalization, and we have gener...

2023-04-12 02:26:28 ET Summary The White House's announcement on drug price caps caused a significant drop in biopharma stocks during Q1 2023. The impact of drug pricing-related caps and pressure will likely be limited, and the industry is expected to adapt and find new revenue st...

Summary WuXi Biologics outlicensed global rights for up to four pre-clinical bi- and multi-specific TCE antibodies to GSK in a $1.5 billion agreement. ArriVent Biopharma of Philadelphia is raising another $145 million to bring drugs from China and other emerging biotech hubs to the US m...

Summary China pharma company Jinxi Jemincare out-licensed global rights for its androgen receptor degrader to Roche in a $650 million agreement. The oral small-molecule candidate, developed in Jemincare’s R&D center, is currently in preclinical testing. Shanghai IASO Bi...

Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. Baron International Growth Fund (the “Fund”) declined 16.18% (Institutional Shares) during the second quart...

Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. Baron Emerging Markets Fund (the “Fund”) declined 10.33% (Institutional Shares) during the second quarter o...

Pfizer ( NYSE: PFE ) backed Chinese cancer drugmaker CStone Pharmaceuticals ( OTCPK:CSPHF ) is exploring strategic options, including a sale of the company, Bloomberg News reported citing people with knowledge of the matter. WuXi Healthcare Ventures, a unit of...